A phase II, multicenter, randomized, open-label study to evaluate the safety and tolerability of proxalutamide (GT0918) in subjects with metastatic castrate-resistant prostate cancer (mCRPC).-MedSci.cn

A phase II, multicenter, randomized, open-label study to evaluate the safety and tolerability of proxalutamide (GT0918) in subjects with metastatic castrate-resistant prostate cancer (mCRPC).

Zhou, T; Ye, DW; Sun, ZQ; Meng, QG; He, DL; Shi, GW; Jin, J; Sun, WB; Chen, LJ; Liu, B; Wang, JE; Cheng, JE; Hu, ZQ; Yang, Y; Song, XS; Wang, YH; Fu, C; Zhou, QX; Tong, YZ; Sun, YH

JOURNAL OF CLINICAL ONCOLOGY, 2021; 39 (6):

科室
- - 订阅+
  - 更多科室
工具
服务

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

A phase II, multicenter, randomized, open-label study to evaluate the safety and tolerability of proxalutamide (GT0918) in subjects with metastatic castrate-resistant prostate cancer (mCRPC).

科室

工具

服务